GCLLSG trial results to be presented at the 2016 ASH Annual Meeting
A new prognostic tool for CLL: CLL-IPI
Choosing treatment options for CLL and combining novel drugs
Inherited and acquired genetic factors involved in the development of CLL
John Gribben et al.
TGR-1202- a new generation PI3K delta inhibitor for CLL